Zai Lab Limited-ADR

Zai Lab Limited is a research-based, commercial stage, global biopharmaceutical company headquartered in Shanghai, China. The firm is engaged in the discovery, licensing, development, and commercialisation of proprietary therapeutics that primarily address areas of unmet medical need in the fields of infectious diseases, oncology, and autoimmune diseases. The company was founded in 2014. The company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. The firm has also brought various products to market in China, including Zejula which is a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, Optune, which is for the treatment of patients with newly diagnosed glioblastoma, and Qinlock, which is for the treatment of adult patients with advanced gastrointestinal stromal tumour. The firm has built an internal Research & Development centre as well as their own manufacturing facilities in China and has become a trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market and develop long-term strategic partnerships for global clinical development. The firm is listed on the NASDAQ where it trades under the ticker ZLAB. Track the share price of ZLAB by adding it to your eToro virtual portfolio.